SPTX (Seaport Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SPTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-24 | ROBERT J. HOMBACH | Director | Buy | — | — |
| 2026-05-06 | PureTech Health plc | 10%+ Owner | C | — | — |
| 2026-05-04 | Sharon Mates | Director | A | — | — |
| 2026-05-04 | STEVEN M PAUL | Director | C | — | — |
| 2026-05-04 | Daphne Zohar | Chief Executive Officer | A | — | — |
| 2026-05-04 | David E. Wheadon | Director | A | — | — |
| 2026-05-04 | SANDRA E PETERSON | Director | A | — | — |
| 2026-05-04 | Lana Gladstein | General Counsel | C | — | — |
| 2026-05-04 | Denice Torres | Director | C | — | — |
| 2026-05-04 | Lauren White | Chief Financial Officer | C | — | — |
| 2026-05-04 | Antony Loebel | Chief Medical Officer | C | — | — |
| 2026-05-04 | Michael Cunyuan Chen | Chief Scientific Officer | C | — | — |
| 2026-05-04 | JAMES HEALY | Director | C | — | — |
| 2026-05-04 | ROBERT J. HOMBACH | Director | A | — | — |
| 2026-05-04 | STEVEN GILLIS | 10%+ Owner | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 13,038,493 | — |
| — | 10%+ Owner | 6,294,951 | — |
| — | Director | 2,731,538 | — |
| — | Director | 863,031 | — |
| — | General Counsel | 33,515 | — |
| — | Chief Medical Officer | 20,109 | — |
| — | Director | 13,406 | — |
| — | Director | 13,000 | — |
| — | Chief Financial Officer | 6,702 | — |
| — | Chief Scientific Officer | 3,351 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SPTX quote page; the site-wide leaderboard is on the insider transactions hub.